ReproCELL Incorporated (4978.T)
JPY 103.0
(0.0%)
JPY 103.0
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.42 Billion JPY | -17.83% |
| 2022 | 2.95 Billion JPY | 32.16% |
| 2021 | 2.23 Billion JPY | 73.72% |
| 2020 | 1.28 Billion JPY | 7.2% |
| 2019 | 1.19 Billion JPY | 10.23% |
| 2018 | 1.08 Billion JPY | 17.52% |
| 2017 | 926.25 Million JPY | -26.36% |
| 2016 | 1.25 Billion JPY | 17.95% |
| 2015 | 1.06 Billion JPY | 88.07% |
| 2014 | 567 Million JPY | 23.01% |
| 2013 | 460.95 Million JPY | 9.73% |
| 2012 | 420.07 Million JPY | 32.72% |
| 2011 | 316.52 Million JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 619 Million JPY | -4.78% |
| 2023 Q1 | 556.37 Million JPY | -23.78% |
| 2023 FY | 2.42 Billion JPY | -17.83% |
| 2023 Q4 | 650.05 Million JPY | 3.24% |
| 2023 Q3 | 629.62 Million JPY | 6.58% |
| 2023 Q2 | 590.76 Million JPY | 6.18% |
| 2022 Q1 | 666.75 Million JPY | -10.67% |
| 2022 FY | 2.95 Billion JPY | 32.16% |
| 2022 Q4 | 729.99 Million JPY | 12.91% |
| 2022 Q3 | 646.52 Million JPY | -28.95% |
| 2022 Q2 | 910 Million JPY | 36.48% |
| 2021 FY | 2.23 Billion JPY | 73.72% |
| 2021 Q4 | 746.39 Million JPY | 49.55% |
| 2021 Q3 | 499.09 Million JPY | -17.67% |
| 2021 Q2 | 606.24 Million JPY | 58.35% |
| 2021 Q1 | 382.84 Million JPY | 13.53% |
| 2020 Q2 | 446.72 Million JPY | 165.49% |
| 2020 FY | 1.28 Billion JPY | 7.2% |
| 2020 Q1 | 168.26 Million JPY | -45.44% |
| 2020 Q3 | 334.08 Million JPY | -25.22% |
| 2020 Q4 | 337.21 Million JPY | 0.94% |
| 2019 Q3 | 326.69 Million JPY | 6.03% |
| 2019 FY | 1.19 Billion JPY | 10.23% |
| 2019 Q4 | 308.38 Million JPY | -5.61% |
| 2019 Q1 | 256.71 Million JPY | -9.12% |
| 2019 Q2 | 308.11 Million JPY | 20.02% |
| 2018 FY | 1.08 Billion JPY | 17.52% |
| 2018 Q4 | 282.47 Million JPY | 5.74% |
| 2018 Q3 | 267.15 Million JPY | -6.03% |
| 2018 Q2 | 284.3 Million JPY | 11.67% |
| 2018 Q1 | 254.59 Million JPY | 6.4% |
| 2017 Q1 | 211.04 Million JPY | -46.89% |
| 2017 Q4 | 239.28 Million JPY | -0.69% |
| 2017 Q3 | 240.95 Million JPY | 2.55% |
| 2017 Q2 | 234.96 Million JPY | 11.33% |
| 2017 FY | 926.25 Million JPY | -26.36% |
| 2016 Q1 | 266.24 Million JPY | -3.47% |
| 2016 FY | 1.25 Billion JPY | 17.95% |
| 2016 Q4 | 397.34 Million JPY | 15.59% |
| 2016 Q3 | 343.74 Million JPY | 37.24% |
| 2016 Q2 | 250.47 Million JPY | -5.92% |
| 2015 Q3 | 250.76 Million JPY | -9.14% |
| 2015 Q2 | 275.99 Million JPY | 4.63% |
| 2015 Q1 | 263.78 Million JPY | 13.27% |
| 2015 Q4 | 275.82 Million JPY | 9.99% |
| 2015 FY | 1.06 Billion JPY | 88.07% |
| 2014 Q1 | 87.53 Million JPY | -37.28% |
| 2014 Q4 | 232.88 Million JPY | 60.8% |
| 2014 Q3 | 144.82 Million JPY | 42.32% |
| 2014 Q2 | 101.76 Million JPY | 16.25% |
| 2014 FY | 567 Million JPY | 23.01% |
| 2013 FY | 460.95 Million JPY | 9.73% |
| 2013 Q3 | 134.72 Million JPY | 32.62% |
| 2013 Q1 | 85.08 Million JPY | 0.0% |
| 2013 Q2 | 101.58 Million JPY | 19.4% |
| 2013 Q4 | 139.55 Million JPY | 3.59% |
| 2012 FY | 420.07 Million JPY | 32.72% |
| 2011 FY | 316.52 Million JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 4.77 Billion JPY | 49.124% |
| PRISM BioLab Co.,LTD | 112.92 Million JPY | -2049.033% |
| GNI Group Ltd. | 26.01 Billion JPY | 90.67% |
| Linical Co., Ltd. | 12.3 Billion JPY | 80.282% |
| Trans Genic Inc. | 13.08 Billion JPY | 81.451% |
| MEDINET Co., Ltd. | 661.54 Million JPY | -266.842% |
| Soiken Holdings Inc. | 5.15 Billion JPY | 52.955% |
| Cytori Cell Research Institute, Inc. | 1.56 Billion JPY | -55.527% |
| AnGes, Inc. | 152.98 Million JPY | -1486.31% |
| OncoTherapy Science, Inc. | 610.11 Million JPY | -297.762% |
| Nxera Pharma Co., Ltd. | 12.76 Billion JPY | 80.99% |
| Immuno-Biological Laboratories Co., Ltd. | 816.7 Million JPY | -197.149% |
| NanoCarrier Co., Ltd. | 135.5 Million JPY | -1690.903% |
| Carna Biosciences, Inc. | 1.62 Billion JPY | -49.261% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 428.36 Million JPY | -466.532% |
| RaQualia Pharma Inc. | 1.9 Billion JPY | -27.646% |
| Chiome Bioscience Inc. | 682.46 Million JPY | -255.596% |
| Kidswell Bio Corporation | 2.43 Billion JPY | 0.182% |
| PeptiDream Inc. | 28.71 Billion JPY | 91.548% |
| Oncolys BioPharma Inc. | 63.03 Million JPY | -3749.768% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | 121 Million JPY | -1905.634% |
| BrightPath Biotherapeutics Co., Ltd. | 72 Thousand JPY | -3370479.167% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 39.88 Million JPY | -5984.23% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 4.51 Billion JPY | 46.197% |
| FunPep Company Limited | 530 Thousand JPY | -457790.0% |
| Kringle Pharma, Inc. | 69.25 Million JPY | -3404.429% |
| Stella Pharma Corporation | 269.49 Million JPY | -800.519% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | 316.81 Million JPY | -665.997% |
| Cuorips Inc. | 23.1 Million JPY | -10404.792% |
| K Pharma,Inc. | 1 Billion JPY | -142.682% |
| Takara Bio Inc. | 43.5 Billion JPY | 94.422% |
| PhoenixBio Co., Ltd. | 1.71 Billion JPY | -41.479% |
| StemCell Institute Inc. | 2.48 Billion JPY | 2.192% |
| Japan Tissue Engineering Co., Ltd. | 2.51 Billion JPY | 3.475% |
| CellSeed Inc. | 190.13 Million JPY | -1176.372% |